Remus Pharmaceuticals Ltd vs Supriya Lifescience Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Remus Pharmaceuticals Ltd is ₹ 685.3 as of 30 Apr 15:30 . The P/E Ratio of Remus Pharmaceuticals Ltd is 49.4 as of March 2024 .The P/E Ratio of Supriya Lifescience Ltd is 0 as of March 2024 . The Market Cap of Remus Pharmaceuticals Ltd is ₹ 1016 crore as of March 2024 .The Market Cap of Supriya Lifescience Ltd is ₹ 0 crore as of March 2024 . The revenue of Remus Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Supriya Lifescience Ltd for the Dec '25 is ₹ 209.05 crore as compare to the Sep '25 revenue of ₹ 202.56 crore. This represent the growth of 3.2% The ebitda of Remus Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Supriya Lifescience Ltd for the Dec '25 is ₹ 74.24 crore as compare to the Sep '25 ebitda of ₹ 75.37 crore. This represent the decline of -1.5% The net profit of Remus Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Supriya Lifescience Ltd changed from ₹ 44.64 crore to ₹ 49.68 crore over 7 quarters. This represents a CAGR of 6.30% The Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 4.44 % on March 2025 . This represents a CAGR of 20.15% over 3 yearsThe Dividend Payout of Supriya Lifescience Ltd changed from 3.2 % on March 2021 to 4.28 % on March 2025 . This represents a CAGR of 5.99% over 5 years .

About Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

About Supriya Lifescience Ltd

Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'.
The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007.
Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai. The Company commenced operations in April, 2008.
It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs).
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development.

FAQs for the comparison of Remus Pharmaceuticals Ltd and Supriya Lifescience Ltd

Which company has a larger market capitalization, Remus Pharmaceuticals Ltd or Supriya Lifescience Ltd?

Market cap of Remus Pharmaceuticals Ltd is 807 Cr while Market cap of Supriya Lifescience Ltd is 5,589 Cr

What are the key factors driving the stock performance of Remus Pharmaceuticals Ltd and Supriya Lifescience Ltd?

The stock performance of Remus Pharmaceuticals Ltd and Supriya Lifescience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Remus Pharmaceuticals Ltd and Supriya Lifescience Ltd?

As of May 4, 2026, the Remus Pharmaceuticals Ltd stock price is INR ₹685.3. On the other hand, Supriya Lifescience Ltd stock price is INR ₹694.5.

How do dividend payouts of Remus Pharmaceuticals Ltd and Supriya Lifescience Ltd compare?

To compare the dividend payouts of Remus Pharmaceuticals Ltd and Supriya Lifescience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.